Quick Order

PD-L1 / B7-H1 / CD274 Antibody, Rabbit MAb

  • PD-L1 / B7-H1 / CD274 Antibody, Rabbit MAb, Immunohistochemistry
DatasheetReviewsRelated ProductsProtocols
Human CD274 Antibody Product Information
Immunogen:Recombinant Human PD-L1 / B7-H1 / CD274 protein (Catalog#10084-H08H)
Clone ID:015
Ig Type:Rabbit IgG
Concentration:
Endotoxin:
Formulation:0.2 μm filtered solution in PBS
Preparation:This antibody was obtained from a rabbit immunized with purified, recombinant Human PD-L1 / B7-H1 / CD274 (rh PD-L1 / B7-H1 / CD274; Catalog#10084-H08H; NP_054862.1; Met 1-Thr 239).
Human CD274 Antibody IHC Application Image
PD-L1 / B7-H1 / CD274 Antibody, Rabbit MAb, Immunohistochemistry
[Click to enlarge image]
Caption:
Immunochemical staining of human B7H1 in human placenta with rabbit monoclonal antibody (5 µg/mL, formalin-fixed paraffin embedded sections). Positive staining was localized to trophoblast.
Other CD274 Antibody Products
PD-L1/B7-H1/CD274 Background

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

Immune Checkpoint
Immune Checkpoint Blockade: Blocking Antibodies   Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking Antibodies
Immune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies   Immune Checkpoint Detection: IHC Antibodies   Immune Checkpoint Detection: ICC Antibodies   Immune Checkpoint Detection: FCM Antibodies   Immune Checkpoint Detection: WB Antibodies
Immune Checkpoint Proteins   PD-L1 / B7-H1 / CD274 Immune Checkpoint Proteins
Immune Checkpoint Targets   Co-inhibitory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Human PD-L1/B7-H1/CD274 References
  • Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
  • Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
  • Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
  • Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
  • Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
  • Product nameProduct name
    Size / Price
    Catalog: 10084-R015-50
    List Price: 
    Price:      (You Save: )

    Datasheet & Documentation

    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"